Quoin had approximately $5.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The Company believes that this, together with the $16.6 million upfront funding received in the private placement which closed in October 2025 and the $3.3 million received from warrant exercises in October 2025, will support operations into 2027.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin recruits three additional patients to Netherton Syndrome study
- Quoin Pharmaceuticals Advances in Netherton Syndrome Treatment Study
- Quoin Pharmaceuticals’ QRX003 Lotion Study: A Potential Breakthrough for Netherton Syndrome
- Quoin Pharmaceuticals’ QRX003 Lotion: A Promising Study for Netherton Syndrome
- Quoin Pharmaceuticals Receives FDA Orphan Drug Designation